nodes	percent_of_prediction	percent_of_DWPC	metapath
Dihydroxyaluminium—TNNC1—Striated Muscle Contraction—TPM2—esophageal cancer	0.0431	0.149	CbGpPWpGaD
Dihydroxyaluminium—TNNC1—Striated Muscle Contraction—TPM2—esophageal cancer	0.0367	0.127	CbGpPWpGaD
Dihydroxyaluminium—Venous thrombosis—Carboplatin—esophageal cancer	0.0348	0.103	CcSEcCtD
Dihydroxyaluminium—TNNC1—Striated Muscle Contraction—TPM4—esophageal cancer	0.0327	0.113	CbGpPWpGaD
Dihydroxyaluminium—VDAC2—epithelium—esophageal cancer	0.0312	0.0838	CbGeAlD
Dihydroxyaluminium—Fluid overload—Carboplatin—esophageal cancer	0.0302	0.0892	CcSEcCtD
Dihydroxyaluminium—TNNC1—Muscle contraction—TPM2—esophageal cancer	0.029	0.1	CbGpPWpGaD
Dihydroxyaluminium—TNNC1—Striated Muscle Contraction—TPM1—esophageal cancer	0.0278	0.0963	CbGpPWpGaD
Dihydroxyaluminium—TNNC1—Striated Muscle Contraction—TPM4—esophageal cancer	0.0278	0.0962	CbGpPWpGaD
Dihydroxyaluminium—VDAC3—bronchus—esophageal cancer	0.0256	0.0688	CbGeAlD
Dihydroxyaluminium—VDAC3—smooth muscle tissue—esophageal cancer	0.025	0.0673	CbGeAlD
Dihydroxyaluminium—VDAC1—epithelium—esophageal cancer	0.0247	0.0664	CbGeAlD
Dihydroxyaluminium—VDAC1—bronchus—esophageal cancer	0.0243	0.0654	CbGeAlD
Dihydroxyaluminium—VDAC1—smooth muscle tissue—esophageal cancer	0.0238	0.064	CbGeAlD
Dihydroxyaluminium—VDAC2—digestive system—esophageal cancer	0.0237	0.0638	CbGeAlD
Dihydroxyaluminium—TNNC1—Striated Muscle Contraction—TPM1—esophageal cancer	0.0236	0.0818	CbGpPWpGaD
Dihydroxyaluminium—VDAC3—trachea—esophageal cancer	0.023	0.0617	CbGeAlD
Dihydroxyaluminium—TNNC1—Muscle contraction—TPM4—esophageal cancer	0.022	0.076	CbGpPWpGaD
Dihydroxyaluminium—VDAC1—trachea—esophageal cancer	0.0219	0.0587	CbGeAlD
Dihydroxyaluminium—Extravasation—Carboplatin—esophageal cancer	0.0216	0.0636	CcSEcCtD
Dihydroxyaluminium—VDAC2—lung—esophageal cancer	0.0198	0.0533	CbGeAlD
Dihydroxyaluminium—VDAC3—digestive system—esophageal cancer	0.0198	0.0531	CbGeAlD
Dihydroxyaluminium—VDAC1—digestive system—esophageal cancer	0.0188	0.0505	CbGeAlD
Dihydroxyaluminium—TNNC1—Muscle contraction—TPM1—esophageal cancer	0.0187	0.0646	CbGpPWpGaD
Dihydroxyaluminium—Diuresis—Cisplatin—esophageal cancer	0.0178	0.0525	CcSEcCtD
Dihydroxyaluminium—Haemolysis—Cisplatin—esophageal cancer	0.0173	0.0512	CcSEcCtD
Dihydroxyaluminium—Blindness transient—Methotrexate—esophageal cancer	0.0166	0.0489	CcSEcCtD
Dihydroxyaluminium—VDAC3—lung—esophageal cancer	0.0165	0.0444	CbGeAlD
Dihydroxyaluminium—Phlebitis—Carboplatin—esophageal cancer	0.0158	0.0467	CcSEcCtD
Dihydroxyaluminium—VDAC1—lung—esophageal cancer	0.0157	0.0422	CbGeAlD
Dihydroxyaluminium—VDAC2—lymph node—esophageal cancer	0.0136	0.0364	CbGeAlD
Dihydroxyaluminium—TNNC1—lung—esophageal cancer	0.0135	0.0362	CbGeAlD
Dihydroxyaluminium—VDAC3—lymph node—esophageal cancer	0.0113	0.0303	CbGeAlD
Dihydroxyaluminium—VDAC1—lymph node—esophageal cancer	0.0107	0.0289	CbGeAlD
Dihydroxyaluminium—Venous thrombosis—Cisplatin—esophageal cancer	0.0102	0.0301	CcSEcCtD
Dihydroxyaluminium—TNNC1—lymph node—esophageal cancer	0.00921	0.0247	CbGeAlD
Dihydroxyaluminium—Fluid overload—Cisplatin—esophageal cancer	0.00887	0.0262	CcSEcCtD
Dihydroxyaluminium—Venous thrombosis—Capecitabine—esophageal cancer	0.00753	0.0222	CcSEcCtD
Dihydroxyaluminium—Infection—Carboplatin—esophageal cancer	0.00666	0.0197	CcSEcCtD
Dihydroxyaluminium—Encephalopathy—Capecitabine—esophageal cancer	0.00633	0.0187	CcSEcCtD
Dihydroxyaluminium—Extravasation—Cisplatin—esophageal cancer	0.00632	0.0186	CcSEcCtD
Dihydroxyaluminium—Pain—Carboplatin—esophageal cancer	0.00574	0.0169	CcSEcCtD
Dihydroxyaluminium—Body temperature increased—Carboplatin—esophageal cancer	0.0053	0.0156	CcSEcCtD
Dihydroxyaluminium—VDAC1—Metabolism of proteins—XBP1—esophageal cancer	0.005	0.0173	CbGpPWpGaD
Dihydroxyaluminium—VDAC1—Metabolism of proteins—SLC30A7—esophageal cancer	0.0048	0.0166	CbGpPWpGaD
Dihydroxyaluminium—Encephalopathy—Methotrexate—esophageal cancer	0.00471	0.0139	CcSEcCtD
Dihydroxyaluminium—Phlebitis—Cisplatin—esophageal cancer	0.00465	0.0137	CcSEcCtD
Dihydroxyaluminium—Polyuria—Cisplatin—esophageal cancer	0.00456	0.0135	CcSEcCtD
Dihydroxyaluminium—VDAC1—Metabolism of proteins—ST6GAL1—esophageal cancer	0.00432	0.015	CbGpPWpGaD
Dihydroxyaluminium—Lung disorder—Methotrexate—esophageal cancer	0.00428	0.0126	CcSEcCtD
Dihydroxyaluminium—Hyponatraemia—Cisplatin—esophageal cancer	0.00402	0.0119	CcSEcCtD
Dihydroxyaluminium—Dehydration—Cisplatin—esophageal cancer	0.00372	0.011	CcSEcCtD
Dihydroxyaluminium—Extravasation—Methotrexate—esophageal cancer	0.00347	0.0102	CcSEcCtD
Dihydroxyaluminium—Phlebitis—Capecitabine—esophageal cancer	0.00343	0.0101	CcSEcCtD
Dihydroxyaluminium—Thrombophlebitis—Capecitabine—esophageal cancer	0.00341	0.0101	CcSEcCtD
Dihydroxyaluminium—Polyuria—Capecitabine—esophageal cancer	0.00336	0.00991	CcSEcCtD
Dihydroxyaluminium—Thirst—Capecitabine—esophageal cancer	0.0031	0.00915	CcSEcCtD
Dihydroxyaluminium—VDAC1—Metabolism of proteins—ACTB—esophageal cancer	0.00298	0.0103	CbGpPWpGaD
Dihydroxyaluminium—Hyponatraemia—Capecitabine—esophageal cancer	0.00296	0.00874	CcSEcCtD
Dihydroxyaluminium—Urinary retention—Capecitabine—esophageal cancer	0.00281	0.00828	CcSEcCtD
Dihydroxyaluminium—Coma—Methotrexate—esophageal cancer	0.00277	0.00816	CcSEcCtD
Dihydroxyaluminium—Dehydration—Capecitabine—esophageal cancer	0.00274	0.0081	CcSEcCtD
Dihydroxyaluminium—VDAC1—Metabolism of proteins—HSPA5—esophageal cancer	0.00269	0.00931	CbGpPWpGaD
Dihydroxyaluminium—Visual impairment—Cisplatin—esophageal cancer	0.00267	0.00787	CcSEcCtD
Dihydroxyaluminium—VDAC1—Metabolism of proteins—CALR—esophageal cancer	0.00261	0.00902	CbGpPWpGaD
Dihydroxyaluminium—VDAC1—Metabolism of proteins—GHRL—esophageal cancer	0.00256	0.00887	CbGpPWpGaD
Dihydroxyaluminium—Thrombophlebitis—Methotrexate—esophageal cancer	0.00254	0.00749	CcSEcCtD
Dihydroxyaluminium—VDAC1—Metabolism of proteins—FBXW7—esophageal cancer	0.00252	0.00872	CbGpPWpGaD
Dihydroxyaluminium—Polyuria—Methotrexate—esophageal cancer	0.0025	0.00738	CcSEcCtD
Dihydroxyaluminium—Angina pectoris—Capecitabine—esophageal cancer	0.00248	0.00733	CcSEcCtD
Dihydroxyaluminium—Visual disturbance—Methotrexate—esophageal cancer	0.00232	0.00684	CcSEcCtD
Dihydroxyaluminium—Vision blurred—Cisplatin—esophageal cancer	0.00227	0.0067	CcSEcCtD
Dihydroxyaluminium—Convulsion—Cisplatin—esophageal cancer	0.00209	0.00616	CcSEcCtD
Dihydroxyaluminium—Rhinitis—Capecitabine—esophageal cancer	0.00205	0.00604	CcSEcCtD
Dihydroxyaluminium—Oedema—Cisplatin—esophageal cancer	0.00197	0.0058	CcSEcCtD
Dihydroxyaluminium—Visual impairment—Capecitabine—esophageal cancer	0.00197	0.0058	CcSEcCtD
Dihydroxyaluminium—Infection—Cisplatin—esophageal cancer	0.00195	0.00577	CcSEcCtD
Dihydroxyaluminium—Tachycardia—Cisplatin—esophageal cancer	0.00192	0.00567	CcSEcCtD
Dihydroxyaluminium—Hypotension—Cisplatin—esophageal cancer	0.00184	0.00542	CcSEcCtD
Dihydroxyaluminium—Chills—Capecitabine—esophageal cancer	0.00183	0.0054	CcSEcCtD
Dihydroxyaluminium—Back pain—Capecitabine—esophageal cancer	0.00172	0.00507	CcSEcCtD
Dihydroxyaluminium—Pain—Cisplatin—esophageal cancer	0.00168	0.00496	CcSEcCtD
Dihydroxyaluminium—Vision blurred—Capecitabine—esophageal cancer	0.00167	0.00494	CcSEcCtD
Dihydroxyaluminium—Vertigo—Capecitabine—esophageal cancer	0.0016	0.00471	CcSEcCtD
Dihydroxyaluminium—Body temperature increased—Cisplatin—esophageal cancer	0.00156	0.00459	CcSEcCtD
Dihydroxyaluminium—Visual impairment—Methotrexate—esophageal cancer	0.00146	0.00432	CcSEcCtD
Dihydroxyaluminium—Oedema—Capecitabine—esophageal cancer	0.00145	0.00428	CcSEcCtD
Dihydroxyaluminium—Hypersensitivity—Cisplatin—esophageal cancer	0.00145	0.00428	CcSEcCtD
Dihydroxyaluminium—Infection—Capecitabine—esophageal cancer	0.00144	0.00425	CcSEcCtD
Dihydroxyaluminium—Tachycardia—Capecitabine—esophageal cancer	0.00142	0.00418	CcSEcCtD
Dihydroxyaluminium—Chills—Methotrexate—esophageal cancer	0.00136	0.00402	CcSEcCtD
Dihydroxyaluminium—Hypotension—Capecitabine—esophageal cancer	0.00136	0.004	CcSEcCtD
Dihydroxyaluminium—Diarrhoea—Cisplatin—esophageal cancer	0.00135	0.00397	CcSEcCtD
Dihydroxyaluminium—Back pain—Methotrexate—esophageal cancer	0.00128	0.00378	CcSEcCtD
Dihydroxyaluminium—Vomiting—Cisplatin—esophageal cancer	0.00125	0.00369	CcSEcCtD
Dihydroxyaluminium—Vision blurred—Methotrexate—esophageal cancer	0.00125	0.00368	CcSEcCtD
Dihydroxyaluminium—Pain—Capecitabine—esophageal cancer	0.00124	0.00366	CcSEcCtD
Dihydroxyaluminium—Vertigo—Methotrexate—esophageal cancer	0.00119	0.00351	CcSEcCtD
Dihydroxyaluminium—Nausea—Cisplatin—esophageal cancer	0.00117	0.00345	CcSEcCtD
Dihydroxyaluminium—Urticaria—Capecitabine—esophageal cancer	0.00115	0.0034	CcSEcCtD
Dihydroxyaluminium—Body temperature increased—Capecitabine—esophageal cancer	0.00115	0.00338	CcSEcCtD
Dihydroxyaluminium—Convulsion—Methotrexate—esophageal cancer	0.00115	0.00338	CcSEcCtD
Dihydroxyaluminium—Infection—Methotrexate—esophageal cancer	0.00107	0.00316	CcSEcCtD
Dihydroxyaluminium—Hypersensitivity—Capecitabine—esophageal cancer	0.00107	0.00315	CcSEcCtD
Dihydroxyaluminium—Hypotension—Methotrexate—esophageal cancer	0.00101	0.00298	CcSEcCtD
Dihydroxyaluminium—Diarrhoea—Capecitabine—esophageal cancer	0.000992	0.00293	CcSEcCtD
Dihydroxyaluminium—Dizziness—Capecitabine—esophageal cancer	0.000959	0.00283	CcSEcCtD
Dihydroxyaluminium—Pain—Methotrexate—esophageal cancer	0.000923	0.00272	CcSEcCtD
Dihydroxyaluminium—Vomiting—Capecitabine—esophageal cancer	0.000922	0.00272	CcSEcCtD
Dihydroxyaluminium—Nausea—Capecitabine—esophageal cancer	0.000862	0.00254	CcSEcCtD
Dihydroxyaluminium—Urticaria—Methotrexate—esophageal cancer	0.000858	0.00253	CcSEcCtD
Dihydroxyaluminium—Body temperature increased—Methotrexate—esophageal cancer	0.000854	0.00252	CcSEcCtD
Dihydroxyaluminium—Hypersensitivity—Methotrexate—esophageal cancer	0.000796	0.00235	CcSEcCtD
Dihydroxyaluminium—Diarrhoea—Methotrexate—esophageal cancer	0.000739	0.00218	CcSEcCtD
Dihydroxyaluminium—Dizziness—Methotrexate—esophageal cancer	0.000714	0.00211	CcSEcCtD
Dihydroxyaluminium—Vomiting—Methotrexate—esophageal cancer	0.000687	0.00203	CcSEcCtD
Dihydroxyaluminium—Nausea—Methotrexate—esophageal cancer	0.000641	0.00189	CcSEcCtD
